FUGAZZOLA, LAURA
FUGAZZOLA, LAURA
Dipartimento di Scienze della Salute
Patient-Derived in Vitro Models Reveal Insights into Medullary Thyroid Cancer Microenvironment and Resistance to Tyrosine Kinase Inhibitors
2026 E. Grassi, V. Ghiandai, G. Gaudenzi, E. Massardi, V. Cirello, E. Carbone, D. Gentilini, S. Uraghi, G. Gazzano, G. Dionigi, C. Colombo, G. Vitale, L. Fugazzola, L. Persani
Fibrosis‐Driven Surgical Risk After Thyroid Nodule Ablation: Quantitative Clinicopathological Determinants of Complications in Post‐Ablative Thyroidectomy—A Retrospective Cohort Study
2026 D. Zhang, A. Boero, G. Gazzano, A. Satta, L. Fugazzola, C. Colombo, F. Brucchi, G. Dionigi
High-dose intravenous methylprednisolone is effective in subacute thyroiditis unresponsive to oral steroids
2026 S. Rodolfi, G.M. Vannucchi, M. Perrino, C. Colombo, D. Covelli, L. Persani, L. Fugazzola, I. Campi
How genetics changed or will change the therapy in thyroid nodules with indeterminate cytology?
2026 M. Muzza, C. Colombo, L. Fugazzola, L. Persani
Validation of the 2025 ATA risk stratification system in a cohort of patients with papillary thyroid carcinoma
2026 C. Moneta, M. Trevisan, C. Colombo, A. De Luca, M. Lugaresi, G. Reali, G. Gazzano, L. Persani, L. Fugazzola, S. De Leo
Development of a sensitive plasma lenvatinib quantification method and validation in thyroid cancer patients
2026 C. Colombo, R. Ottria, M. Trevisan, E. Carbone, C. Moneta, M. Lugaresi, S. Casati, S. Vanerio, D. Ceruti, M. Succi, V. Cirello, S. De Leo, L. Persani, P. Ciuffreda, L. Fugazzola
Clinical presentation and outcomes of medullary thyroid cancer in two European countries: impact of diagnostic strategies.
2026 D. Ceruti, H. Bonenkamp, C. Colombo, M. Gotthardt, S. De Leo, A. Van Herwaarden, P. Ottevanger, R. Netea-Maier, L. Fugazzola
TP53 Alterations Associate with Poor Response to Lenvatinib in Patients with Advanced Thyroid Cancer
2025 V. Cirello, C. Colombo, D. Tosi, A. Manzo, M.O. Borghi, U. Gianelli, G. Gazzano, S. Ferrero, G. Dionigi, L. Persani, L. Fugazzola
Endocrinological toxicities related to immunotherapy combinations for advanced renal cell carcinoma: Practical expert-based management recommendations
2025 C. Colombo, S. De Leo, I. Campisi, E. Palesandro, F. Turco, C. Buttigliero, L. Fugazzola, M. Tucci
Beyond Malignancy Risk Stratification: FNAC Report Anticipates Thyroid Cancer Staging. Insights From Recent Studies
2025 M. Rotondi, M. Endo, M. Teliti, A. Crescenzi, I. Azaryan, L. Croce, R. Elisei, L. Fugazzola, E.S. Cibas, P. Trimboli, J.A. Sipos
Changing the paradigm: lobectomy for sporadic medullary thyroid cancer
2025 M. Lugaresi, C. Moneta, G. Saruggia, G. Dionigi, G. Gazzano, L. Fugazzola
Utility of ultra-portable ultrasound devices for the risk-stratification of thyroid dysfunctions in an emergency setting
2025 I. Campi, L. Fugazzola
Differentiated thyroid cancer in two European referral centres: impact of different diagnostic and therapeutic strategies
2025 D. Ceruti, P. B Ottevanger, S. De Leo, H. J Bonenkamp, C. Colombo, M. Gotthardt, L. Fugazzola, R. T Netea-Maier
Will the autofluorescence take over inadvertent parathyroidectomy?Results from a multicentre cohort study
2025 D. Barbieri, P. Indelicato, S. DE LEO, C. Moneta, S. Coccia, G. Gazzano, L. Giordano, F. LIRA LUCE, D. Canta, L. Fugazzola, M. Bussi, G. Dionigi, M. Trevisan
Exploring the tumor suppressor role of RIN1 in familial thyroid carcinoma
2025 L. Picello, M. Dalle Nogare, D. Puggina, C. Salvoro, G. Pennelli, G. Gaudenzi, S. Carra, M. Oldani, D. Gentilini, L. Fugazzola, A. Faggiano, G. Vitale, G. Occhi, G. Vazza
Physical activity and systemic treatment outcomes in advanced thyroid cancer.
2025 C. Colombo, D. Ceruti, F. Cervellini, M. Succi, S. De Leo, M. Trevisan, C. Moneta, M. Lugaresi, G. Dionigi, G. Gazzano, L. Persani, L. Fugazzola
La lobectomia come trattamento iniziale del carcinoma midollare tiroideo sporadico: uno studio prospettico
2025 M. Lugaresi, A. De Luca, G. Saruggia, G. Dionigi, G. Gazzano, M. Muzza, L. Persani, C. Colombo, L. Fugazzola
Impatto della dose iniziale sul trattamento con lenvatinib nel carcinoma tiroideo differenziato avanzato
2025 C. Moneta, M. Trevisan, C. Colombo, M. Succi, M. Lugaresi, D. Ceruti, S. De Leo, L. Fugazzola
Genetic modification of the AJCC classification of papillary thyroid cancer: an international, multicentre, retrospective cohort study.
2025 M. Xing, S. Lin, A. Mathur, Y. Li, B. Bendlova, V. Kuklikova, M. Melo, T. Jesus, P. Soares, C. Colombo, L. Fugazzola, N. Mitsutake, M. Matsuse, A. Sako, A. Estrada-Florez, L. Carvajal-Carmona, M. Bohórquez, C. Mian, F. Vianello, C. O'Neill, R. Clifton-Bligh, A. Czarniecka, B. Jarzab, C. Jung, B. Brahma, P. Ladenson, Y. Park
Clinical relevance of the thyroid differentiation score (TDS) in benign and malignant thyroid tumors
2025 M. Muzza, C. Colombo, G. Pogliaghi, E. Carbone, L. Ermellino, M. Succi, C. Moneta, G. Dionigi, D. Gentilini, G. Vannucchi, G. Gazzano, L. Persani, L. Fugazzola